US 3655679A
· Shen et al.
· 1972
[cited by applicant]
US 3703582A
· Shen et al.
· 1972
[cited by applicant]
US 3894920A
· Kondo et al.
· 1975
[cited by applicant]
US 4016287A
· Eberhardt et al.
· 1977
[cited by applicant]
US 5397799A
· Kress et al.
· 1995
[cited by applicant]
US 5405613A
· Rowland
· 1995
[cited by applicant]
US 5607954A
· Weidmann et al.
· 1997
[cited by applicant]
US 5610172A
· Weidmann et al.
· 1997
[cited by applicant]
US 5620995A
· Weidmann et al.
· 1997
[cited by applicant]
US 5620996A
· Weidmann et al.
· 1997
[cited by applicant]
US 5658933A
· Weidmann et al.
· 1997
[cited by applicant]
US 5719164A
· Weidmann et al.
· 1998
[cited by applicant]
US 5726305A
· Weidmann et al.
· 1998
[cited by applicant]
US 6020350A
· Weidmann et al.
· 2000
[cited by applicant]
US 6093730A
· Weidmann et al.
· 2000
[cited by applicant]
US 6159379A
· Means et al.
· 2000
[cited by applicant]
US 6420427B1
· Takahashi et al.
· 2002
[cited by applicant]
US 6566088B1
· Mcknight et al.
· 2003
[cited by applicant]
US 6589758B1
· Zhu
· 2003
[cited by applicant]
US 7183287B2
· Durley
· 2007
[cited by applicant]
US 7323475B2
· Arend et al.
· 2008
[cited by applicant]
US 7588924B2
· Evdokimov et al.
· 2009
[cited by applicant]
US 7811595B2
· Kawamoto et al.
· 2010
[cited by applicant]
US 8050873B2
· Evdokimov et al.
· 2011
[cited by applicant]
US 8124582B2
· Guenzler-Pukall et al.
· 2012
[cited by applicant]
US 8129376B2
· Sundaresan et al.
· 2012
[cited by applicant]
US 8273773B2
· Brameld et al.
· 2012
[cited by applicant]
US 8323671B2
· Wu et al.
· 2012
[cited by applicant]
US 8343952B2
· Wu et al.
· 2013
[cited by applicant]
US 8512972B2
· Evdokimov et al.
· 2013
[cited by applicant]
US 8530404B2
· Seeley et al.
· 2013
[cited by applicant]
US 8598210B2
· Kawamoto et al.
· 2013
[cited by applicant]
US 8722895B2
· Kawamoto et al.
· 2014
[cited by applicant]
US 8865748B2
· Shalwitz et al.
· 2014
[cited by applicant]
US 8940773B2
· Kawamoto et al.
· 2015
[cited by applicant]
US 9145366B2
· Lanthier et al.
· 2015
[cited by applicant]
US 9598370B2
· Kawamoto et al.
· 2017
[cited by applicant]
US 9701636B2
· Copp et al.
· 2017
[cited by applicant]
US 9776969B2
· Lanthier et al.
· 2017
[cited by applicant]
US 9987262B2
· Copp et al.
· 2018
[cited by applicant]
US RE47437E
· Kawamoto et al.
· 2019
[cited by applicant]
US 20020192737A1
· Kaelin et al.
· 2002
[cited by applicant]
US 20030153503A1
· Klaus et al.
· 2003
[cited by applicant]
US 20030176317A1
· Guenzler-Pukall et al.
· 2003
[cited by applicant]
US 20040235082A1
· Fourney et al.
· 2004
[cited by applicant]
US 20040254215A1
· Arend et al.
· 2004
[cited by applicant]
US 20060142389A1
· Aurell et al.
· 2006
[cited by applicant]
US 20060276477A1
· Klaus et al.
· 2006
[cited by applicant]
US 20070105899A1
· Suzuki et al.
· 2007
[cited by applicant]
US 20070154482A1
· Sukhatme et al.
· 2007
[cited by applicant]
US 20070203174A1
· Klimko et al.
· 2007
[cited by applicant]
US 20070213335A1
· Fitch et al.
· 2007
[cited by applicant]
US 20070299086A1
· Kawamoto
· 2007
[cited by applicant]
US 20080124740A1
· Evdokimov et al.
· 2008
[cited by applicant]
US 20080213404A1
· Johnson et al.
· 2008
[cited by applicant]
US 20090023666A1
· Gardiner et al.
· 2009
[cited by applicant]
US 20090082357A1
· Fitch et al.
· 2009
[cited by applicant]
US 20090240475A1
· Evdokimov et al.
· 2009
[cited by applicant]
US 20100021423A1
· Brameld et al.
· 2010
[cited by applicant]
US 20100331303A1
· Kawamoto et al.
· 2010
[cited by applicant]
US 20100331374A1
· Wu et al.
· 2010
[cited by applicant]
US 20110077400A1
· Lobben et al.
· 2011
[cited by applicant]
US 20110305776A1
· Ho et al.
· 2011
[cited by applicant]
US 20120282627A1
· Evdokimov et al.
· 2012
[cited by applicant]
US 20120309977A1
· Lanthier et al.
· 2012
[cited by applicant]
US 20120316204A1
· Shalwitz et al.
· 2012
[cited by applicant]
US 20120329836A1
· Marsh et al.
· 2012
[cited by applicant]
US 20130022974A1
· Chinnaiyan et al.
· 2013
[cited by applicant]
US 20130203816A1
· Kawamoto et al.
· 2013
[cited by applicant]
US 20130245076A1
· Kawamoto et al.
· 2013
[cited by applicant]
US 20140045899A1
· Kawamoto et al.
· 2014
[cited by applicant]
US 20140057892A1
· Kawamoto et al.
· 2014
[cited by applicant]
US 20150119425A1
· Kawamoto et al.
· 2015
[cited by applicant]
US 20150141467A1
· Copp et al.
· 2015
[cited by applicant]
US 20150361043A1
· Lanthier et al.
· 2015
[cited by applicant]
US 20160009648A1
· Kawamoto et al.
· 2016
[cited by applicant]
US 20160199434A1
· Eubank et al.
· 2016
[cited by applicant]
US 20160214939A1
· Hanselmann et al.
· 2016
[cited by applicant]
US 20160339005A1
· Shalwitz et al.
· 2016
[cited by applicant]
US 20170189387A1
· Kawamoto et al.
· 2017
[cited by applicant]
US 20170258773A1
· Copp et al.
· 2017
[cited by applicant]
US 20170362178A1
· Lanthier et al.
· 2017
[cited by applicant]
US 20180065933A1
· Hanselmann
· 2018
[cited by applicant]
US 20180280365A1
· Copp et al.
· 2018
[cited by applicant]
CA 2098158A1
· 1993
[cited by applicant]
CA 2253282A1
· 1997
[cited by applicant]
CN 105837502A
· 2016
[cited by applicant]
CN 106146491A
· 2016
[cited by applicant]
CN 111320577A
· 2020
[cited by applicant]
EP 0650960A1
· 1995
[cited by applicant]
EP 0650961A1
· 1995
[cited by applicant]
EP 2044005B1
· 2010
[cited by applicant]
EP 3290404A1
· 2018
[cited by applicant]
EP 3290404B1
· 2019
[cited by applicant]
JP H09221476A
· 1997
[cited by applicant]
JP 2001048786A
· 2001
[cited by applicant]
JP 2007194072A
· 2007
[cited by applicant]
JP 2010527378A
· 2010
[cited by applicant]
WO 9622021A1
· 1996
[cited by applicant]
WO 9744333A1
· 1997
[cited by applicant]
WO 9741103A1
· 1997
[cited by applicant]
WO 9948870A1
· 1999
[cited by applicant]
WO 02074980A2
· 2002
[cited by applicant]
WO 02074981A2
· 2002
[cited by applicant]
WO 02083688A1
· 2002
[cited by applicant]
WO 03028663A2
· 2003
[cited by applicant]
WO 03032972A1
· 2003
[cited by applicant]
WO 03049686A2
· 2003
[cited by applicant]
WO 03053997A2
· 2003
[cited by applicant]
WO 03097040A1
· 2003
[cited by applicant]
WO 2004019868A2
· 2004
[cited by applicant]
WO 2004035812A2
· 2004
[cited by applicant]
WO 2004048383A1
· 2004
[cited by applicant]
WO 2004108121A1
· 2004
[cited by applicant]
WO 2005007192A2
· 2005
[cited by applicant]
WO 2005115984A2
· 2005
[cited by applicant]
WO 2005118836A2
· 2005
[cited by applicant]
WO 2006019831A1
· 2006
[cited by applicant]
WO 2006030977A2
· 2006
[cited by applicant]
WO 2006114213A1
· 2006
[cited by applicant]
WO 2006138511A2
· 2006
[cited by applicant]
WO 2007038571A2
· 2007
[cited by applicant]
WO 2007047194A2
· 2007
[cited by applicant]
WO 2007070359A2
· 2007
[cited by applicant]
WO 2007082899A1
· 2007
[cited by applicant]
WO 2007084667A2
· 2007
[cited by applicant]
WO 2007088571A2
· 2007
[cited by applicant]
WO 2007103905A2
· 2007
[cited by applicant]
WO 2007136990A2
· 2007
[cited by applicant]
WO 2007150011A2
· 2007
[cited by applicant]
WO 2008002576A2
· 2008
[cited by applicant]
WO 2008089051A1
· 2008
[cited by applicant]
WO 2008089052A2
· 2008
[cited by applicant]
WO 2008130508A1
· 2008
[cited by applicant]
WO 2008130527A1
· 2008
[cited by applicant]
WO 2008137060A1
· 2008
[cited by applicant]
WO 2008141731A2
· 2008
[cited by applicant]
WO 2008144266A1
· 2008
[cited by applicant]
WO 2009019656A1
· 2009
[cited by applicant]
WO 2009020119A1
· 2009
[cited by applicant]
WO 2009035534A2
· 2009
[cited by applicant]
WO 2009037570A2
· 2009
[cited by applicant]
WO 2009039321A1
· 2009
[cited by applicant]
WO 2009039323A1
· 2009
[cited by applicant]
WO 2009043093A1
· 2009
[cited by applicant]
WO 2009049112A1
· 2009
[cited by applicant]
WO 2009067790A1
· 2009
[cited by applicant]
WO 2009070644A1
· 2009
[cited by applicant]
WO 2009073497A2
· 2009
[cited by applicant]
WO 2009073669A1
· 2009
[cited by applicant]
WO 2009086044A1
· 2009
[cited by applicant]
WO 2009086592A1
· 2009
[cited by applicant]
WO 2009089547A1
· 2009
[cited by applicant]
WO 2009111337A1
· 2009
[cited by applicant]
WO 2010029577A2
· 2010
[cited by applicant]
WO 2010113942A1
· 2010
[cited by applicant]
WO 2010128355A2
· 2010
[cited by applicant]
WO 2011057112A1
· 2011
[cited by applicant]
WO 2012170377A1
· 2012
[cited by applicant]
WO 2012170439A1
· 2012
[cited by applicant]
WO 2012170442A1
· 2012
[cited by applicant]
WO 2013013609A1
· 2013
[cited by applicant]
WO 2014168986A1
· 2014
[cited by applicant]
WO 2014200773A2
· 2014
[cited by applicant]
WO 2015023967A2
· 2015
[cited by applicant]
WO 2015073779A1
· 2015
[cited by applicant]
WO 2015112831A1
· 2015
[cited by applicant]
WO 2016109300A1
· 2016
[cited by applicant]
WO 2016118858A1
· 2016
[cited by applicant]
WO 2016153996A1
· 2016
[cited by applicant]
WO 2016161094A1
· 2016
[cited by applicant]
WO 2019217550A1
· 2019
[cited by applicant]
WO 2021087144A1
· 2021
[cited by applicant]
WO 2021188936A1
· 2021
[cited by applicant]
WO 2021188938A1
· 2021
[cited by applicant]
WO 2021188944A1
· 2021
[cited by applicant]
American Diabetes Association, “Standards of Medical Care in Diabetes-2006”, Diabetes Care, vol. 29, Suppl. 1, Jan. 2006, pp. S4-S42, (39 pages).
[cited by applicant]
CAS Registry Nos. 1261773-17-4, 1261723-73-2, Chemcats, 2011, (2 pages).
[cited by applicant]
CAS Registry Nos. 1261813-98-2, 1261613-86-8, and 1261518-21-1, Chemcats, 2011, (2 pages).
[cited by applicant]
CAS Registry Nos. 1361609-40-6, 1361556-21-9, 1361555-42-1, 1361544-77-5, 1361480- 63-8, 1361477-92-0, Chemcats, 2012, (6 pages).
[cited by applicant]
CAS Registry Nos. 1361809-77-9, 1361737-20-3, 1361721-11-0, 1361693-45-9, 1361676- 79-0, Chemcats, 2012, (5 pages).
[cited by applicant]
ClinicalTrials.gov, Archive No. NCT01235936, Aug. 30, 2012, retrieved Dec. 1, 2014 from URL: http://clinicaltrials.gov/archive/NCT01235936/2012_09_30, (3 pages).
[cited by applicant]
Decision of the Technical Board of Appeal of the European Patent Office for Case No. T 0777/08 dated May 24, 2011, retrieved Dec. 19, 2017 from URL: https://www.epo.org/boards-of-appeal/decisions/pdf/t080777ex1.pdf (17 …
[cited by applicant]
“Akebia Closes $41 Million Series C”, Triathlon Medical Ventures, Jun. 4, 2013, retrieved Dec. 1, 2014 from URL: http://www.tmvp.com/news_Akebia_06042013.html, (3 pages).
[cited by applicant]
“Hippuric Acid Sodium Salt”, Science Lab.com: Chemicals & Laboratory Equipment, retrieved Mar. 11, 2010 from URL: http://web.archive.org/web/20041107121553/http://sciencelab.com/page/S/PVAR/10415/SLH2620, (1 page).
[cited by applicant]
“International Preliminary Report on Patentability”, International Preliminary Report on Patentability, Ch. I, for PCT/US2019/031310 dated Nov. 19, 2020 (6 pages), Nov. 19, 2020.
[cited by applicant]
“International Search Report and Written Opinion”, International Search Report and Written Opinion for PCT/US2019/031310 dated Aug. 7, 2019 (10 pages), Aug. 7, 2019.
[cited by applicant]
“SCHEMBL3484399”, PubChem, National Center for Biotechnology Information, CID 49848485, Jan. 31, 2011, retrieved Mar. 15, 2016 from URL: https://pubchem.ncbi.nlm.nih.gov/compound/49848485, (13 pages).
[cited by applicant]
“XEADCOHJERWFOI-UHFFFAOYSA-M”, PubChem, National Center for Biotechnology Information, CID 71491828, Jun. 10, 2013, retrieved Mar. 21, 2016 from URL: https://pubchem.ncbi.nlm.nih.gov/compound/71491828, (12 pages).
[cited by applicant]
Acker, Till , et al., “Genetic evidence for a tumor suppressor role of HIF-2α”, Cancer Cell, vol. 8, No. 2, Aug. 2005, pp. 131-141, DOI: 10.1016/j.ccr.2005.07.003, (11 pages).
[cited by applicant]
Alesso, Sonia M, et al., “Improving resins for solid phase synthesis: incorporation of 1-[2-(2-methoxyethoxy)ethoxy]-4-vinyl-benzene”, Tetrahedron, vol. 59, No. 36, Sep. 1, 2003, pp. 7163-7169, DOI: 10.1016/S0040-4020(0…
[cited by applicant]
Altschul, Stephen F, et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”, Nucleic Acids Research, vol. 25, No. 17, Sep. 1, 1997, pp. 3389-3402, DOI: 10.1093/nar/25.17.3389, (14 pag…
[cited by applicant]
Anderson, Neal G, “Chapter 12—Crystallization and Purification”, Practical Process Research and Development (Second Edition), 2012, pp. 329-364, DOI: 10.1016/B978-0-12-386537-3.00012-5, (38 pages).
[cited by applicant]
Anderson, Wayne K., et al., “Antileukemic activity of derivatives of 1,2-dimethyl-3,4-bis(hydroxymethyl)-5-phenylpyrrole bis(N-methylcarbamate)”, Journal of Medicinal Chemistry, vol. 22, No. 8, 1979, pp. 977-980, DOI: 1…
[cited by applicant]
Annex, Brian H., et al., “Growth factor-induced therapeutic angiogenesis in the heart: protein therapy”, Cardiovascular Research, vol. 65, No. 3, Feb. 2005, pp. 649-655, DOI: 10.1016/j.cardiores.2004.09.004, (7 pages).
[cited by applicant]
Ardelt, Agnieszka A., et al., “Estradiol Regulates Angiopoietin-1 mRNA Expression Through Estrogen Receptor-α in a Rodent Experimental Stroke Model”, Stroke, vol. 36, No. 2, Feb. 2005, pp. 337-341, DOI: 10.1161/01.STR.0…
[cited by applicant]
Auerbach, Robert , et al., “Angiogenesis Assays: A Critical Overview”, Clinical Chemistry, vol. 49, No. 1, 2003, pp. 32-40, DOI: 10.1373/49.1.32, (9 pages).
[cited by applicant]
Barany, George , et al., “Solid-phase peptide synthesis: a silver anniversary report”, Chemical Biology & Drug Design, vol. 30, No. 6, 1987, pp. 705-739, DOI: 10.1111/j.1399-3011.1987.tb03385.x, (35 pages).
[cited by applicant]
Bartlett, Paul A., et al., “CAVEAT: a program to facilitate the design of organic molecules”, Molecular Recognition in Chemical and Biological Problems, Special Pub., Royal Society of Chemistry, 1989, pp. 182-196 (15 pa…
[cited by applicant]
Böhm, Hans-Joachim , “The computer program LUDI: A new method for the de novo design of enzyme inhibitors”, Journal of Computer-Aided Molecular Design, vol. 6, No. 1, 1992, pp. 61-78, DOI: 10.1007/BF00124387, (18 pages).
[cited by applicant]
Branden, Carl Ivar, et al., “Introduction to Protein Structure, Second Edition”, Garland Science, 1998, pp. 374-375, (4 pages).
[cited by applicant]
Brittain, Harry G., et al., “Polymorphism in Pharmaceutical Solids, Second Edition”, Drugs and Pharmaceutical Sciences, vol. 192, 2009, pp. 333-335, (7 pages).
[cited by applicant]
Burger, Alfred , “Isosterism and bioisosterism in drug design”, Progress in Drug Research, vol. 37, 1991, pp. 287-371, DOI: 10.1007/978-3-0348-7139-6_7, (85 pages).
[cited by applicant]
Bussolino, Federico , et al., “Molecular mechanisms of blood vessel formation”, Trends in Biochemical Sciences, vol. 22, No. 7, Jul. 1997, pp. 251-256, DOI: 10.1016/s0968-0004(97)01074-8, (6 pages).
[cited by applicant]
Byrn, Stephen , et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations”, Pharmaceutical Research, vol. 12, No. 7, 1995, pp. 945-954, DOI: 10.1023/a:1016241927429, (10 pages).
[cited by applicant]
Carey, Francis A., “”, Organic Chemistry, Sixth Edition, McGraw Hill, 2006, Chapter 1, pp. 9, Chapter 19, pp. 839-840, and Chapter 27, pp. 1182-1183, (12 pages).
[cited by applicant]
Catrina, Sergiu-Bogdan , et al., “Hyperglycemia Regulates Hypoxia-Inducible Factor-1a Protein Stability and Function”, Diabetes, vol. 53, No. 12, 2004, pp. 3226-3232, DOI: 10.2337/diabetes.53.12.3226, (7 pages).
[cited by applicant]
Cheeseright, Tim , “The Identification of Bioisosteres as Drug Development Candidates”, Innovations in Pharmaceutical Technology, 2009, (4 pages).
[cited by applicant]
Cherng, Yie-Jia , “Synthesis of substituted pyridines by the reactions of halopyridines with sulfur, oxygen and carbon nucleophiles under focused microwave irradiation”, Tetrahedron, vol. 58, No. 24, Jun. 10, 2002, pp. …
[cited by applicant]
Costello, Leslie C., et al., “Evidence for Changes in RREB-1, ZIP3, and Zinc in the Early Development of Pancreatic Adenocarcinoma”, Journal of Gastrointestinal Cancer, vol. 43, No. 4, 2012, pp. 570-578, DOI: 10.1007/s1…
[cited by applicant]
Cousins, Scott W., “Intravitreal Anti-VEGF and Anti-PDGF Combination Therapy”, Retina Today, Oct. 2009, Retrieved from URL: http://retinatoday.com/2009/10/1009_12.php, (2 pages).
[cited by applicant]
Cunliffe, C. Jane , et al., “Novel inhibitors of prolyl 4-hydroxylase. 3. Inhibition by the substrate analog N-oxaloglycine and its derivatives”, Journal of Medicinal Chemistry, vol. 35, No. 14, 1992, pp. 2652-2658, DOI…
[cited by applicant]
Demetriades, Marina , et al., “Dynamic Combinatorial Chemistry Employing Boronic Acids/Boronate Esters Leads to Potent Oxygenase Inhibitors”, Angewandte Chemie, International Edition , vol. 51, No. 27, Jul. 2, 2012,pp. …
[cited by applicant]
Dranoff, Glenn , “GM-CSF-secreting melanoma vaccines”, Oncogene, vol. 22, 2003, pp. 3188-3192, DOI: 10.1038/sj.onc.1206459, (5 pages).
[cited by applicant]
Elson, David A., et al., “Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α”, Genes & Development, vol. 15, 2001, pp. 2520-2532, DOI: 10.1101/gad…
[cited by applicant]
Elvidge, Gareth P., et al., “Concordant Regulation of Gene Expression by Hypoxia and 2-Oxoglutarate-dependent Dioxygenase Inhibition”, Journal of Biological Chemistry, vol. 281, No. 22, Jun. 2006, pp. 15215-15226, DOI: …
[cited by applicant]
Enoch, Stuart , et al., “ABC of wound healing: Non-surgical and drug treatments”, BMJ, vol. 332, No. 7546, 2006, pp. 900-903, DOI: 10.1074/jbc.M511408200, (4 pages).
[cited by applicant]
Favier, Judith , et al., “HIF2α reduces growth rate but promotes angiogenesis in a mouse model of neuroblastoma”, BMC Cancer, vol. 7, Article No. 139, 2007, DOI: 10.1186/1471-2407-7-139, (10 pages).
[cited by applicant]
Flower, Darren R, et al., “Modelling G-protein-coupled receptors for drug design”, Biochimica et Biophysica Acta (BBA)—Reviews on Biomembranes, vol. 1422, No. 3, Nov. 16, 1999, pp. 207-234, DOI: 10.1016/s0304-4157(99)00…
[cited by applicant]
Folkman, Judah , “Chapter 10—Tumor Angiogenesis”, The Molecular Basis of Cancer, 1995, pp. 206-232, (29 pages).
[cited by applicant]
Franklin, Trevor J, et al., “Approaches to the design of anti-fibrotic drugs”, Biochemical Society Transactions, vol. 19, No. 4, Nov. 1991, pp. 812-815, DOI: 10.1042/bst0190812, (4 pages).
[cited by applicant]
Gaunt, Matthew J, et al., “Rational Design of Benzyl-Type Protecting Groups Allows Sequential Deprotection of Hydroxyl Groups by Catalytic Hydrogenolysis”, Journal of Organic Chemistry, vol. 63, No. 13, 1998, pp. 4172-4…
[cited by applicant]
Gaunt, Matthew J, et al., “Rational Design of Benzyl-Type Protecting Groups Allows Sequential Deprotection of Hydroxyl Groups by Catalytic Hydrogenolysis”, Journal of Organic Chemistry, vol. 63, No. 13, 1998, pp. 4172-4…
[cited by applicant]
Gavhane, Y. N. , et al., “Solid Tumors: Facts, Challenges and Solutions”, International Journal of Pharma Sciences and Research, vol. 2, No. 1, 2011, pp. 1-12, (12 pages).
[cited by applicant]
Goodford, P. J. , et al., “A computational procedure for determining energetically favorable binding sites on biologically important macromolecules”, Journal of Medicinal Chemistry, vol. 28, No. 7, 1985, pp. 849-857, DO…
[cited by applicant]
Goodsell, David S., et al., “Automated docking of substrates to proteins by simulated annealing”, Proteins, vol. 8, No. 3, 1990, pp. 195-202, DOI: 10.1002/prot.340080302, (8 pages).
[cited by applicant]
Greer, Samantha N, et al., “The updated biology of hypoxia-inducible factor”, The EMBO Journal, vol. 31, No. 11, May 30, 2012, pp. 2448-2460, DOI: 10.1038/emboj.2012.125, (13 pages).
[cited by applicant]
Hardcastle, Ian R., et al., “Discovery of Potent Chromen-4-one Inhibitors of the DNA-Dependent Protein Kinase (DNA-PK) Using a Small-Molecule Library Approach”, Journal of Medicinal Chemistry, vol. 48, No. 24, 2005, pp.…
[cited by applicant]
Hoeksema, H. , et al., “Structure of rubradirin”, Journal of the American Chemical Society, vol. 104, No. 19, 1982, pp. 5173-5181, DOI: 10.1021/ja00383a030, (9 pages).
[cited by applicant]
Hu, Cheng-Jun , et al., “Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation”, Molecular and Cellular Biology, vol. 23, No. 24, 2003, pp. 9361-9374, DOI: 10.1128/MCB.23.24.93…
[cited by applicant]
Ingersoll, A. W. , et al., “Hippuric Acid”, Organic Synthesis, CV 2, 328, Retrieved on Mar. 11, 2010 from the Internet at <http://web.archive.org/web/20020724135719/http://www.orgsyn.org/orgsyn/orgsyn/prepContent.asp?pr…
[cited by applicant]
Ivan, Mircea , et al., “Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor”, PNAS, vol. 99, No. 21, Sep. 26, 2002, pp. 13459-13464, DOI: 10.1073/…
[cited by applicant]
Ivan, Mircea , et al., “HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing”, Science, vol. 292, No. 5516, Apr. 5, 2001, pp. 464-468, DOI: 10.1126/science.1059817, (5 pages).
[cited by applicant]
Ivanisevic, Igor , et al., “Uses of X-Ray Powder Diffraction In the Pharmaceutical Industry”, Pharmaceutical Formulation and Quality, 2010, DOI: 10.1002/9780470571224.pse414, (4 pages).
[cited by applicant]
Iyoda, Masahiko , et al., “Homocoupling of Aryl Halides Using Nickel(II) Complex and Zinc in the Presence of Et4NI. An Efficient Method for the Synthesis of Biaryls and Bipyridines”, Bulletin of the Chemical Society of …
[cited by applicant]
Jaakkola, Panu , et al., “Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation”, Science, vol. 292, No. 5516, Apr. 5, 2001, pp. 468-472, DOI: 10.1126/science.1059796, (…
[cited by applicant]
Jones, Gareth , et al., “Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation”, Journal of Molecular Biology, vol. 245, No. 1, 1995, pp. 43-53, DOI: 10.1016/s0022-2836(95)8…
[cited by applicant]
Kaelin, William G., “Proline hydroxylation and gene expression”, Annual Review of Biochemistry, vol. 74, 2005, pp. 115-128, DOI: 10.1146/annurev.biochem.74.082803.133142, (14 pages).
[cited by applicant]
Karuppagounder, Saravanan S, et al., “Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibition: Robust New Target or Another Big Bust for Stroke Therapeutics?”, Journal of Cerebral Blood Flow & Metabolism, vol. 32, No. 7,…
[cited by applicant]
Kawashima, Yoichiro , et al., “Suppressive Effect of Quinolinic Acid and Hippuric Acid on Bone Marrow Erythroid Growth and Lymphocyte Blast Formation in Uremia”, Advances in Experimental Medicine and Biology, vol. 223, …
[cited by applicant]
Ke, Qingdong , et al., “Hypoxia-Inducible Factor-1 (HIF-1)”, Molecular Pharmacology, vol. 70, No. 5, Nov. 2006, pp. 1469-1480, DOI: 10.1124/mol.106.027029, (12 pages).
[cited by applicant]
Khandhadia, Sam , et al., “Age-Related Macular Degeneration”, Neurodegenerative Diseases, Landes Bioscience and Springer Science+Business Media, 2012, pp. 15-36, (22 pages).
[cited by applicant]
Kietzmann, Thomas , et al., “Perivenous expression of the mRNA of the three hypoxia-inducible factor α-subunits, HIF1α, HIF2α and HIF3α, in rat liver”, Biochemical Journal, vol. 354, No. 3, Mar. 2001, pp. 531-537, DOI: …
[cited by applicant]
Kim, so Yeon , et al., “Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications”, Molecules, vol. 20, No. 11, 2015, pp. 20551-20568, DOI: 10.3390/mole…
[cited by applicant]
Kirwan, D.J. , et al., “11-Crystallization in the pharmaceutical and bioprocessing industries”, Handbook of Industrial Crystallization (Second Edition), 2002, pp. 249-266, DOI: 10.1016/B978-075067012-8/50013-6, (20 page…
[cited by applicant]
Krantz, Sanford B, “Erythropoietin”, Blood, vol. 77, No. 3, Feb. 1, 1991, pp. 419-434, DOI: 10.1182/blood.V77.3.419.419, (16 pages).
[cited by applicant]
Kuntz, Irwin D., et al., “A geometric approach to macromolecule-ligand interactions”, Journal of Molecular Biology, vol. 161, No. 2, Oct. 25, 1982, pp. 269-288, DOI: 10.1016/0022-2836(82)90153-x, (20 pages).
[cited by applicant]
Kurti, Laszlo , et al., “Strategic Applications of Named Reactions in Organic Synthesis”, Elsevier, 2005, pp. 448-449, (4 pages).
[cited by applicant]
Langsetmo, Ingrid , et al., “Inhibition of HIF-Prolyl Hydroxylases with FG-4539 IS Neuroprotective in a Mouse Model of Permanent Focal Ischemia”, International Stroke Conference, Kissimmee, Florida, Presentation No. 427…
[cited by applicant]
Lee, Cheolju , et al., “Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel-Lindau”, Enzyme Catalysis and Regulation, vol. 278, No. 9, Feb. 2003, pp. 7558-7563, DO…
[cited by applicant]
Li, Jian , et al., “PR39, a peptide regulator of angiogenesis”, Nature Medicine, vol. 6, No. 1, 2000, pp. 49-55, DOI: 10.1038/71527, (7 pages).
[cited by applicant]
Lima, Lidia Moreira, et al., “Bioisosterism: A Useful Strategy for Molecular Modification and Drug Design”, Current Medicinal Chemistry, vol. 12, No. 1, 2005, pp. 23-49, DOI: 10.2174/0929867053363540, (27 pages).
[cited by applicant]
Liu, Quanyan , et al., “Hypoxia induces genomic DNA demethylation through the activation of HIF-1α and transcriptional upregulation of MAT2A in hepatoma cells”, Molecular Cancer Therapeutics, vol. 10, No. 6, Jun. 1, 201…
[cited by applicant]
Mancini, Donna M, et al., “Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure”, Circulation, vol. 107, No. 2, 2002, pp. 294-299, DOI: 10.1161/01.CIR.0000044914.42696.…
[cited by applicant]
McDonough, Michael A., et al., “Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2)”, PNAS, vol. 103, No. 26, Jun. 27, 2006, pp. 9814-9819, DOI: 10.1073/pnas.0601283103, (6 p…
[cited by applicant]
Miranker, Andrew , et al., “Functionality maps of binding sites: A multiple copy simultaneous search method”, Proteins: Structure, Function and Genetics, vol. 11, No. 1, Sep. 1991, pp. 29-34, DOI: 10.1002/prot.340110104…
[cited by applicant]
Morissette, Sherry L., et al., “High-throughput crystallization: polymorphs, salts, co- crystals and solvates of pharmaceutical solids”, Advanced Drug Delivery Reviews, vol. 56, No. 3, Feb. 23, 2004, pp. 275-300, DOI: 1…
[cited by applicant]
Moss, G.P. , et al., “Glossary of class names of organic compounds and reactivity intermediates based on structure (IUPAC Recommendations 1995”, Pure and Applied Chemistry, vol. 67, Nos. 8/9, 1995, pp. 1307-1375, DOI: 1…
[cited by applicant]
Nguyen, Louis L., et al., “Cellular interactions in vascular growth and differentiation”, International Review of Cytology, vol. 204, 2001, pp. 1-48, DOI: 10.1016/s0074-7696(01)04002-5, (48 pages).
[cited by applicant]
Nielsen, Dorte Lisbet, “Antiangiogenic therapy for breast cancer”, Breast Cancer Research, vol. 12, Article No. 209, 2010, DOI: 10.1186/bcr2642, (16 pages).
[cited by applicant]
Nishibata, Yoshihiko , et al., “Automatic creation of drug candidate structures based on receptor structure. Starting point for artificial lead generation.”, Tetrahedron, vol. 47, No. 43, Nov. 4, 1991, pp. 8985-8990, DO…
[cited by applicant]
Nowak, Jerzy Z, “Age-related macular degeneration (AMD): pathogenesis and therapy”, Pharmacological Reports, vol. 58, 2006, pp. 353-363, (11 pages).
[cited by applicant]
O'Reilly, Michael S., et al., “Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma”, Cell, vol. 79, No. 2, 1994, pp. 315-328, DOI: 10.1016/0092-8674(94)90200…
[cited by applicant]
O'reilly, Michael S., “Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth”, Cell, vol. 88, No. 2, 1997, pp. 277-285, DOI: 10.1016/S0092-8674(00)81848-6, (9 pages).
[cited by applicant]
Pasqualetti, P. , et al., “Circadian rhythm of serum erythropoietin in myelodysplastic syndromes”, European Review for Medical and Pharmacological Sciences, vol. 4, 2000, pp. 111-115 (5 pages).
[cited by applicant]
Pergola, Pablo E., et al., “Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease”, Kidney International, vol. 90, No. 5, Nov. 2016, pp. 1115-1122, …
[cited by applicant]
Peyssonnaux, Carole , et al., “HIF-1α expression regulates the bactericidal capacity of phagocytes”, The Journal of Clinical Investigation, vol. 115, No. 7, Jul. 2005, pp. 1806-1815, DOI: 10.1172/JCI23865, (10 pages).
[cited by applicant]
Piyamongkol, Sirivipa , et al., “Amido-3-hydroxypyridin-4-ones as Iron(III) Ligands”, Chemistry A European Journal, vol. 16, No. 21, Jun. 1, 2010, pp. 6374-6381, DOI: 10.1002/chem.200902455, (8 pages).
[cited by applicant]
Piyamongkol, Sirivipa , et al., “Amido-3-hydroxypyridin-4-ones as Iron(III) Ligands”, Chemistry A European Journal, vol. 16, No. 21, Jun. 1, 2010, pp. 6374-6381, DOI: 10.1002/chem.200902455, Supporting Information (53 p…
[cited by applicant]
Prabhakar, Nanduri R., et al., “Adaptive and Maladaptive Cardiorespiratory Responses to Continuous and Intermittent Hypoxia Mediated by Hypoxia-Inducible Factors 1 and 2”, Physiological Reviews, vol. 92, No. 3, Jul. 201…
[cited by applicant]
Qian, Jia Qi, et al., “A Randomized, Double-Bind, Placebo Controlled Trial FG-4592 for Correction of Anemia in Subjects with Chronic Kidney Disease in China”, Journal of the American Society of Nephrology, vol. 24, 2013…
[cited by applicant]
Qunibi, Wajeh Y., et al., “A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients”, Ne…
[cited by applicant]
Rahtu-Korpela, Lea , et al., “HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects Against Obesity and Metabolic Dysfunction”, Diabetes, vol. 63, No. 10, 2014, pp. 3324-3333, DOI: 10.…
[cited by applicant]
Rankin, Erinn B., et al., “Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo”, The Journal of Clinical Investigation, vol. 117, No. 4, Apr. 2007, pp. 1068-1077, DOI: 10.1172/JCI30117, (10 pages…
[cited by applicant]
Ratcliffe, Peter J., “HIF-1 and HIF-2: working alone or together in hypoxia?”, The Journal of Clinical Investigation, vol. 117, No. 4, Apr. 2007, 862-865, DOI: 10.1172/JCI31750, (4 pages).
[cited by applicant]
Redondo, Pedro , et al., “Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine downregulates VEGF production in vitro”, Cytokine, vol. 12, No. 4, Apr. 2000, pp. 374-378, DOI: 10.1006/cyto.1999.0566, …
[cited by applicant]
Roda, Julie M., et al., “Stabilization of HIF-2α Induces sVEGFR-1 Production from Tumor-Associated Macrophages and Decreases Tumor Growth in a Murine Melanoma Model”, The Journal of Immunology, vol. 189, No. 6, Sep. 15,…
[cited by applicant]
Schelhaas, Michael , et al., “Protecting Group Strategies in Organic Synthesis”, Angewandte Chemie, International Edition, vol. 35, No. 18, Oct. 1, 1996, pp. 2056-2083, DOI: 10.1002/anie.199620561, (27 pages).
[cited by applicant]
Schöneberg, Torsten , et al., “Structural basis of G protein-coupled receptor function”, Molecular and Cellular Endocrinology, vol. 151, No. 1-2, May 25, 1999, pp. 181-193, 10.1016/S0303-7207(99)00017-9, (13 pages).
[cited by applicant]
Semenza, Gregg L, “Regulation of Erythropoiesis by the Hypoxia-Inducible Factor Pathway: Effects of Genetic and Pharmacological Perturbations”, Hematology/Oncology Clinic of North America, vol. 8, No. 5, Oct. 1994, pp. …
[cited by applicant]
Semenza, Gregg L., et al., “HIF-1 and human disease: one highly involved factor”, Genes & Development, vol. 14, No. 16, 2000, pp. 1983-1991, DOI: 10.1101/gad.14.16.1983, (10 pages).
[cited by applicant]
Semenza, Gregg L., et al., “Signal transduction to hypoxia-inducible factor 1”, Biochemical Pharmacology, vol. 64, No. 5-6, Sep. 2002, pp. 993-998, DOI: 10.1016/s0006-2952(02)01168-1, (6 pages).
[cited by applicant]
Semenza, Gregg L., et al., “Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1”, The Journal of Biological Chemistry, vol. 269, No. 38, Sep. 23, 1994, pp. 23757-23763, (7 pages…
[cited by applicant]
Sexton, Patrick M, et al., “Recent advances in our understanding of peptide hormone receptors and RAMPS”, Current Opinions in Drug Discovery & Development, vol. 2, No. 5, 1999, pp. 440-448, (9 pages).
[cited by applicant]
Sheehan, John T, “3-Hydroxypicolinic Acid and Some of Its Derivatives”, The Journal of Organic Chemistry, vol. 31, No. 2, 1966, pp. 636-638, DOI; 10.1021/jo01340a533, (5 pages).
[cited by applicant]
Siddiq, Ambreena , et al., “Hypoxia-inducible Factor Prolyl 4-Hydroxylase Inhibition. A target for neuroprotection in the central nervous system”, Journal of Biological Chemistry, vol. 280, No. 50, Dec. 2005, pp. 41732-…
[cited by applicant]
Sowter, Heidi M., et al., “Predominant Role of Hypoxia-Inducible Transcription Factor (Hif)-1α versus Hif-2α in Regulation of the Transcriptional Response to Hypoxia”, Cancer Research, vol. 63, No. 19, Oct. 1, 2003, pp.…
[cited by applicant]
Sporn, Michael B., et al., “Chemoprevention of cancer”, Carcinogenesis, vol. 21, No. 3, Mar. 2000, pp. 525-530, DOI: 10.1093/carcin/21.3.525, (6 pages).
[cited by applicant]
Stille, John K., et al., “The Palladium-Catalyzed Cross-Coupling Reactions of Organotin Reagents with Organic Electrophiles”, Angewandte Chemie, International Edition, vol. 25, No. 6, Jun. 1986, pp. 508-524, DOI: 10.100…
[cited by applicant]
Stohlawetz, Petra Jilma, et al., “Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans”, Blood, vol. 95, No. 9, May 1, 2000, pp. 2983-2989 (7 pages).
[cited by applicant]
Sutter, Carrie Hayes, et al., “Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations”, PNAS, vol. 97, No. 9, Apr. 11, 2000,…
[cited by applicant]
Teicher, Beverly A., et al., “Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents”, International Journal of Cancer, vol. 57, No. 6, Jun. 15, 1994, pp. 920-925, DOI: 10.1002…
[cited by applicant]
Thoppil, Roslin J, et al., “Terpenoids as potential chemopreventive and therapeutic agents in liver cancer”, World Journal of Hepatology, vol. 3, No. 9, 2011, pp. 228-249, DOI: 10.4254/wjh.v3.i9.228, (22 pages).
[cited by applicant]
Thornber, C. W. , et al., “Isosterism and molecular modification in drug design”, Chemical Society Reviews, No. 8, 1979, 563-580, DOI: 10.1039/CS9790800563, (18 pages).
[cited by applicant]
Tzschucke, Carl Christoph, et al., “Fluorous-Silica-Supported Perfluoro-Tagged Palladium Complexes Catalyze Suzuki Couplings in Water”, Helvetica Chima Acta, vol. 87, No. 11, Nov. 2004, pp. 2882-2889, DOI: 10.1002/hlca.…
[cited by applicant]
Ullman, F. , et al., “Ueber Synthesen in der Biphenyireihe”, Ber. Deutsch. Chem. Ges., 1901, pp. 2174, (12 pages).
[cited by applicant]
Variankaval, Narayan , et al., “From form to function: Crystallization of active pharmaceutical ingredients”, AlChE Journal, vol. 54, No. 7, Jul. 2008, pp. 1682-1688, DOI: 10.1002/aic.11555, (7 pages).
[cited by applicant]
Vickerstaffe, Emma , et al., “Fully Automated Polymer-Assisted Synthesis of 1,5-Biaryl Pyrazoles”, Journal of Combinatorial Chemistry, vol. 6, 2004, pp. 332-339, DOI: 10.1021/cc049977g, (8 pages).
[cited by applicant]
Vincent, Karen A., et al., “Angiogenesis Is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1α/VP16 Hybrid Transcription Factor”, Circulation, vol. 102, No. 18, Oct. 31, 2000, pp. 2255-2261, …
[cited by applicant]
Vippagunta, Sudha R., et al., “Crystalline solids”, Advanced Drug Delivery Reviews, vol. 48, No. 1, May 16, 2001, pp. 3-26, DOI: 10.1016/S0169-409X(01)00097-7, (23 pages).
[cited by applicant]
Wade, L. G. , et al., “Organic Chemistry”, Wade et al., Organic Chemistry, Sixth Edition, 2005, pp. 780-781, (5 pages).
[cited by applicant]
Warnecke, Christina , et al., “Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors”, The FASEB Journal, vol. 17, No. 9, 2003, pp. 1186-1188,…
[cited by applicant]
Warshakoon, Namal C., et al., “Design and synthesis of substituted pyridine derivatives as HIF-1α prolyl hydroxylase inhibitors”, Bioorganic & Medicinal Chemistry Letters, vol. 16, No. 21, Nov. 1, 2006, pp. 5616-5620, D…
[cited by applicant]
Wax, Stephen D., et al., “SM-20 is a novel 40-kd protein whose expression in the arterial wall is restricted to smooth muscle”, Laboratory Investigation, vol. 74, No. 4, 1996, pp. 797-808, (12 pages).
[cited by applicant]
Weidner, Noel , et al., “Tumor Angiogenesis and Metastasis—Correlation in Invasive Breast Carcinoma”, The New England Journal of Medicine, vol. 324, No. 1, pp. 1-8, DOI: 10.1056/NEJM199101033240101, (111 pages).
[cited by applicant]
Wiesener, Michael S., et al., “Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs”, The FASEB Journal, vol. 17, No. 2, 2003, pp. 271-273, DOI: 10.1096/fj.02-0445fje, (…
[cited by applicant]
Wright, Gary , et al., “Activation of the Prolyl Hydroxylase Oxygen-sensor Results in Induction of GLUT1, Heme Oxygenase-1, and Nitric-oxide Synthase Proteins and Confers Protection from Metabolic Inhibition to Cardiomy…
[cited by applicant]
Wu, Florence T.H., et al., “A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use”, Journal of Cellular and Molecular Medicine, vol. 14, No. 3, Apr. 21, 2010, pp. 528-552…
[cited by applicant]
Yang, Linlin , et al., “Desmoplakin acts as a tumor suppressor by inhibition of the Wnt/β-catenin signaling pathway in human lung cancer”, Carcinogenesis, vol. 33, No. 10, Oct. 2012, pp. 1863-1870, DOI: 10.1093/carcin/b…
[cited by applicant]